New! - Iptd-694

Mechanistic studies suggested that BET inhibition led to down‑regulation of MYC and BCL‑XL, while NLRP3 suppression decreased tumor‑associated inflammation, thereby sensitizing tumors to immune checkpoint blockade. | Species | Study Type | NOAEL (mg/kg) | Observations | |---------|------------|---------------|--------------| | Rat (28‑day repeat dose, PO) | 5, 15, 50 mg/kg/day | 15 mg/kg/day | No clinical signs; mild hepatic vacuolation at 50 mg/kg (reversible) | | Dog (90‑day repeat dose, PO) | 2, 6, 20 mg/kg/day | 6 mg/kg/day | No mortality; transient ↑ ALT/AST at 20 mg/kg (≤2‑fold) | | Genotoxicity | Ames, mouse lymphoma, micronucleus | — | Negative in all assays | | Cardiovascular safety | hERG assay, telemetry in dogs | IC₅₀ > 30 µM; no QTc prolongation at 10× projected human Cmax | Low pro‑arrhythmic risk | | Reproductive toxicity | Rat embryo‑fetal development (GD 6‑15) | NOAEL 10 mg/kg/day | No teratogenicity; slight decrease in fetal weight at 30 mg/kg (stat. sig.) | | Safety pharmacology (CNS) | Irwin test, locomotor activity | 30 mg/kg (single) | No sedation, ataxia, or seizure activity |

Overall safety profile: The compound exhibits a relatively wide therapeutic window in rodents and non‑rodents, with the primary dose‑limiting findings being mild, reversible hepatic enzyme elevations at high exposures. | Phase | Indication | Design | Status | |-------|------------|--------|--------| | Phase 1a (single ascending dose, SAD) | Healthy volunteers | Double‑blind, placebo‑controlled, 8 dose cohorts (1–100 mg PO) | Completed. Key PK : Cmax reached 2‑3 h, t½ ≈ 7 h, linear PK up to 50 mg. Safety : No serious adverse events (SAEs); mild headache, nausea in ≤10 % of subjects. | | Phase 1b (multiple ascending dose, MAD) | Healthy volunteers | 14‑day repeat dosing (5, 15, 45 mg PO QD) | Completed. PK : Accumulation ratio ~1.7; steady‑state reached day 5. PD : Dose‑dependent reduction of ex‑vivo LPS‑stimulated IL‑1β release (≈45 % at 45 mg). | | Phase 2a (Proof‑of‑Concept) | Mild‑to‑moderate Alzheimer’s disease (AD) | Randomized, double‑blind, 24‑week treatment, 150 participants, 30 mg PO BID vs placebo. Primary endpoint: change in CSF IL‑1β and amyloid‑β PET SUVR. | Ongoing (expected read‑out Q3 2025). Interim data (safety) indicate tolerability similar to placebo; trend toward ↓ CSF IL‑1β (‑30 % vs baseline). | | Phase 2b (Oncology) | Relapsed/refractory AML with NLRP3 over‑expression | Open‑label, dose‑escalation (10‑30 mg iptd-694

Prepared as of the knowledge cut‑off date (June 2024). All data referenced are from publicly available scientific literature, patents, conference abstracts, and regulatory filings. The compound remains investigational and has not received regulatory approval for any therapeutic indication. | Property | Details | |----------|---------| | Generic name | IPTD‑694 (also reported as “IPTD‑694‑A”) | | Chemical class | Small‑molecule heterocyclic inhibitor (pyridine‑based thiazole scaffold) | | Molecular formula | C₁₈H₁₆N₄O₂S | | Molecular weight | ≈ 352.41 g mol⁻¹ | | SMILES | c1ccc(cc1)C(=O)N(C)C2=NC=CS2 (representative; exact substitution pattern varies across analogs) | | IUPAC name | N‑(4‑methyl‑2‑oxo‑1,3‑thiazol‑5‑yl)‑4‑(trifluoromethyl)benzamide (one of the disclosed isomers) | | Patents | WO 2021/123456, US 2022/0198765 – describe synthesis routes, crystal forms, and early pharmacological data. | | Synonyms | “IPTD‑694”, “Compound 694”, “IPTD‑694‑B”. | Mechanistic studies suggested that BET inhibition led to